Why the study?
Does perioperative β-blocker exposure reduce 30-day all-cause mortality and cardiovascular morbidity in patients undergoing major noncardiac, nonvascular surgery?
Does perioperative β-blocker exposure reduce 30-day all-cause mortality and cardiovascular morbidity in patients undergoing major noncardiac, nonvascular surgery?
Perioperative beta-blockade is associated with reduced 30-day mortality in patients undergoing major noncardiac, nonvascular surgery who have 2 or more Revised Cardiac Risk Index factors.
Authors
No takes yet. Share an insight, caveat, or question.
Supports selective perioperative β-blocker use in high-RCRI patients; hypothesis-generating and requires RCT confirmation.
London et al. (2013) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: